Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.76 and traded as high as $2.00. Fortress Biotech shares last traded at $1.89, with a volume of 193,180 shares changing hands.
Fortress Biotech Stock Performance
The stock's 50-day simple moving average is $1.86 and its 200 day simple moving average is $1.76. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.72 and a quick ratio of 1.55.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of FBIO. Wolverine Trading LLC acquired a new position in shares of Fortress Biotech during the 4th quarter worth about $26,000. XTX Topco Ltd acquired a new position in shares of Fortress Biotech during the 4th quarter worth about $62,000. Jane Street Group LLC acquired a new stake in shares of Fortress Biotech during the fourth quarter worth about $69,000. PFG Investments LLC increased its position in shares of Fortress Biotech by 28.4% during the first quarter. PFG Investments LLC now owns 45,259 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Weaver Consulting Group boosted its stake in shares of Fortress Biotech by 101.8% during the first quarter. Weaver Consulting Group now owns 46,417 shares of the biopharmaceutical company's stock worth $72,000 after buying an additional 23,419 shares during the period. Institutional investors and hedge funds own 96.51% of the company's stock.
About Fortress Biotech
(
Get Free Report)
Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
Recommended Stories
Before you consider Fortress Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.
While Fortress Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
